The Backstop
Cerebral Bifurcation Aneurysms
Key Facts
About NeuroMedica
NeuroMedica is a clinical-stage medical device company targeting the $500M+ cerebral aneurysm treatment market with a patented flow diverter designed for bifurcation aneurysms. Its core innovation, The Backstop, is positioned as a single-device solution that avoids contact with the weakened aneurysm wall and preserves perforator vessels, potentially offering superior safety and efficacy. The company is backed by strong intellectual property from Cornell University, initial funding from the Helmsley Charitable Trust, and guided by a renowned physician advisory board. NeuroMedica is currently in the development and fundraising stage, seeking to advance its technology toward clinical trials and regulatory approval.
View full company profile